US FDA clears Lantern Pharma and Starlight Therapeutics’ IND for a planned phase 1 paediatric CNS cancer trial of STAR-001: Dallas Monday, March 30, 2026, 14:00 Hrs [IST] Lanter ...
The trial aims to enrol 18 to 42 patients aged one to 17 years and will be carried out at 15 centres.
The conservationist and TV personality says doctors dismissed her pain as “part of being a woman” – now she’s urging ...
Q4 2025 Earnings Call March 30, 2026 4:30 PM EDTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid Margrave ...